1. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

   • Lars Erik Kristensen
   • Rieke Alten
   • Arnold G. Vulto

   Current Opinion Open access 29 September 2018 Pages: 397 - 404

   

2. Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade^®

   • Richard Melsheimer
   • Melissa Calmann
   • Donald Neblock

   Current Opinion Open access 24 August 2018 Pages: 405 - 414

   

3. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

   • Feng Huang
   • Zu-chun Luo

   Systematic Review 10 September 2018 Pages: 415 - 423

   

4. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

   • Beate Bittner
   • Wolfgang Richter
   • Johannes Schmidt

   Review Article Open access 24 July 2018 Pages: 425 - 440

   

5. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

   • Bushra Husain
   • Diego Ellerman

   Review Article Open access 21 August 2018 Pages: 441 - 464

   

6. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates

   • Eshita Khera
   • Greg M. Thurber

   Review Article 21 August 2018 Pages: 465 - 480

   

7. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

   • Pottayil G. Sasikumar
   • Murali Ramachandra

   Review Article 30 August 2018 Pages: 481 - 497

   

8. Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey

   • Rovshan M. Ismailov
   • Zaytuna D. Khasanova

   Original Research Article 17 August 2018 Pages: 499 - 506

   

9. SB5: An Adalimumab Biosimilar

   • James E. Frampton

   Adis Biosimilar Brief 24 September 2018 Pages: 507 - 510

   

10. ABP 980: A Trastuzumab Biosimilar

    • Sohita Dhillon

    Adis Biosimilar Brief 27 September 2018 Pages: 511 - 514

    

11. PF-05280014: A Trastuzumab Biosimilar

    • Julia Paik

    Adis Biosimilar Brief 03 October 2018 Pages: 515 - 518

    

12. Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”

    • Christopher J. Webster
    • Gillian R. Woollett

    Letter to the Editor Open access 16 August 2018 Pages: 519 - 521

13. Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”

    • Francois-Xavier Frapaise

    Letter to the Editor 16 August 2018 Pages: 523 - 523

14. Correction to: GP2015: An Etanercept Biosimilar

    • Emma D. Deeks

    Correction Open access 01 August 2018 Pages: 525 - 525